HOB Biotech Group Corp Ltd (688656) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.019x

Based on the latest financial reports, HOB Biotech Group Corp Ltd (688656) has a cash flow conversion efficiency ratio of 0.019x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥15.28 Million ≈ $2.24 Million USD) by net assets (CN¥820.01 Million ≈ $119.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 688656 equity financing ratio to measure how much of total assets are equity-financed.

HOB Biotech Group Corp Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how HOB Biotech Group Corp Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check HOB Biotech Group Corp Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.

HOB Biotech Group Corp Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of HOB Biotech Group Corp Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
AP (Thailand) Public Company Limited BK:AP	0.039x
Huachangda Intelligent Equipment Group Co Ltd SHE:300278	0.035x
Anhui Estone Materials Technology Co Ltd SHG:688733	-0.014x
Hyperliquid Strategies Inc Common Stock NASDAQ:PURR	N/A
Maccura Biotechnology Co Ltd SHE:300463	0.024x
Bank Sinarmas Tbk JK:BSIM	0.273x
Luoxin Pharmaceuticals Group Stock Co Ltd SHE:002793	0.077x
Shenzhen Centralcon Investment Holding Co Ltd SHE:000042	0.767x

Annual Cash Flow Conversion Efficiency for HOB Biotech Group Corp Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of HOB Biotech Group Corp Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see 688656 market cap.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥820.01 Million ≈ $119.99 Million	CN¥72.94 Million ≈ $10.67 Million	0.089x	-28.63%
2024-12-31	CN¥812.14 Million ≈ $118.84 Million	CN¥101.22 Million ≈ $14.81 Million	0.125x	-1.61%
2023-12-31	CN¥810.73 Million ≈ $118.64 Million	CN¥102.69 Million ≈ $15.03 Million	0.127x	+69.36%
2022-12-31	CN¥779.57 Million ≈ $114.08 Million	CN¥58.31 Million ≈ $8.53 Million	0.075x	-45.04%
2021-12-31	CN¥770.00 Million ≈ $112.68 Million	CN¥104.79 Million ≈ $15.33 Million	0.136x	-51.76%
2020-12-31	CN¥206.39 Million ≈ $30.20 Million	CN¥58.22 Million ≈ $8.52 Million	0.282x	-38.44%
2019-12-31	CN¥149.64 Million ≈ $21.90 Million	CN¥68.57 Million ≈ $10.03 Million	0.458x	+31.16%
2018-12-31	CN¥133.12 Million ≈ $19.48 Million	CN¥46.51 Million ≈ $6.81 Million	0.349x	+24.05%
2017-12-31	CN¥79.03 Million ≈ $11.56 Million	CN¥22.26 Million ≈ $3.26 Million	0.282x	+148.76%
2016-12-31	CN¥56.71 Million ≈ $8.30 Million	CN¥6.42 Million ≈ $939.60K	0.113x	--

About HOB Biotech Group Corp Ltd

SHG:688656 China Medical Devices

Market Cap

$808.92 Million

CN¥5.53 Billion CNY

Market Cap Rank

#9816 Global

#2518 in China

Share Price

CN¥87.03

Change (1 day)

+1.87%

52-Week Range

CN¥78.49 - CN¥213.11

All Time High

CN¥213.11